Citius Pharmaceuticals, Inc. Acquisition Costs, Period Cost
Citius Pharmaceuticals, Inc. (CTXR) reported Acquisition Costs, Period Cost of $19.02 million for the 6-month period ending 2018-03-31, per its 10-Q filed 2018-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AcquisitionCosts · last filed 2018-05-11
- 2018-03-31: Acquisition Costs, Period Cost 6 month $19.02M.
| Period end | Acquisition Costs, Period Cost 6 month |
|---|---|
| 2018-03-31 | $19.02M 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |